Adaptimmune

What a milestone! With the first commercial product order accepted, $ADAP looks forward to bringing this newly FDA-approved cell therapy to more patients in need. adaptimmune.com #CellTherapy #Biotech #Innovation

ICYMI: $ADAP received @US_FDA accelerated approval for the first engineered cell therapy for the treatment of a solid tumor cancer. Announcement here: bit.ly/3AkpUJu #celltherapy #biotech #oncology

#BreakingNews @GalapagosGlobal and $ADAP sign clinical collaboration and exclusive option to license agreement for TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications. bit.ly/4aMsKnc A live webcast will be held on Friday, May 31st at 8am ET. Live webcast and replay can be accessed at bit.ly/3Rv6Jmn

Today $ADAP reported financial results for Q4 and full year ended Dec. 31, 2023, and provided a business update on the progress made in establishing our sarcoma franchise. Release: bit.ly/48GMojA Call replay: bit.ly/4a0DfmZ #biotech #celltherapy #sarcoma

Please join us in welcoming back Cintia Piccina as $ADAP Chief Commercial Officer! Effective March 18, 2024, Cintia returns to lead a rapidly expanding commercial team as it prepares for the launch of afami-cel which, once approved, will be the first engineered TCR T-cell therapy on the market targeting solid tumors. #celltherapy #leadership

BREAKING NEWS: FDA accepts $ADAP application for our investigational engineered T-cell therapy for the treatment of #synovialsarcoma with priority review. Press release here: bit.ly/3HGZ4fd #biotech #fda

$ADAP ICYMI – replay (bit.ly/3NWDyGI) of our presentation at #JPMHC24 – where we outlined our near- and long-term value proposition with our wholly owned cell therapy pipeline. Email investor.relations@adaptimmune.com to schedule time with management.

$ADAP CEO Adrian Rawcliffe spoke today at #JPMHC24 about the company’s sarcoma franchise and work from discovery to delivery of cell therapies with the potential to redefine the treatment of solid tumors. #celltherapy #oncology #biotechnology

$ADAP aims to redefine cancer treatment in solid tumors with cell therapy. For meetings with management email: investor.relations@adaptimmune.com. Presenting at #JPM2024 #JPM24

Our CEO, Adrian Rawcliffe, will present Adaptimmune’s 2024 plans at the J.P. Morgan Healthcare Conference next Thursday, January 11th from 8:15 to 8:55 a.m. PST. Release here: bit.ly/3H2Srnj. The presentation can be accessed live from the Westin, San Francisco or at the webcast and replay link here: bit.ly/3TOBnZI.

$ADAP today announced the completion of the rolling Biologics License Application (BLA) to the FDA for an investigational engineered T-cell therapy for the treatment of advanced #SynovialSarcoma! The first ever BLA to be submitted for an engineered T-cell therapy for solid tumors. See release here: bit.ly/46QTMrv

Today, we announced completion of the transfer of the IND for letetresgene autoluecel (lete-cel) from GSK to $ADAP for the pivotal IGNYTE-ESO (NCT03967223) clinical trial. Data from this trial frame lete-cel as a synergistic product to afami-cel within our cell therapy pipeline. For more information see release: bit.ly/3RkSuAA

ICYMI: $ADAP today announced selection of ADP-600 as a clinical candidate for its best-in-class PRAME strategy. See release for details: bit.ly/3QNFnYA

#News: Today, $ADAP provided its Q3 2023 financial and business update. Release and details for replay can be accessed here: bit.ly/3MAUsKy #earnings #celltherapy #biotechnology

$ADAP and @bvantine1 to present SPEARHEAD-1 trial long-term outcomes data at the #CTOS 2023 Annual Meeting. 39% of patients who received ADAP treatment had clinical responses. 70% of people with advanced disease who responded to ADAP treatment are alive 2 years post-treatment. See link bit.ly/45Y0dZs

$ADAP today presented clinical and translational data from the Ph 1 SURPASS clinical trial at #ESMO23. Data show a 50% response rate in 26 patients with ovarian, urothelial, and head & neck cancers and 75% response rate in these three cancers in patients who received three or fewer prior lines of therapy. See release for more details: bit.ly/46VMcwi